GS

Gurpreet Singh

Active Director Designated Partner DIN 10674649
DIN 10674649 First appointment Jul 2024 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Gurpreet Singh

Data last updated:

Gurpreet Singh is a Designated Partner at Lexera Biotech Llp (since 2024). The company operates in Business Services.

DIN 10674649
Primary Designation Designated Partner
Industry Business Services
First Appointment 20 Jul 2024
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner20 Jul 20242022Active

Board colleagues of Gurpreet Singh

NameDINCompanyDesignation
Karam Chand10001598Lexera Biotech LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Lexera Biotech Llp
Premium access

Shareholding and investment profile for Gurpreet Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gurpreet Singh

Gurpreet Singh currently holds 1 directorship: Lexera Biotech Llp (Designated Partner, since 20 Jul 2024).

Gurpreet Singh was first appointed on 20 Jul 2024 as Designated Partner at Lexera Biotech Llp.

The current boards of Gurpreet Singh's companies include Karam Chand (Lexera Biotech Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available